OBJECTIVE： To explore the effect of comprehensive intervention mode on the rational use of Ribonucleic acid Ⅱ for injection， and to provide reference for the management of adjuvant drugs for cancer therapy. METHODS： The rational use of ribonucleic acid Ⅱ was interfered by establishing evaluation criteria， reviewing medical record， establishing tumor therapy adjuvant management work group， classifying drug prescription right， examining and approving off-label drug use， strengthening the assessment and training， clinical pharmacists intervention. The utilization of ribonucleic acid Ⅱ was analyzed statistically in our hospital during Apr.-Jun. 2015 （before intervention）， Jul.-Sept. 2015 （after the first intervention）， Oct.-Dec. 2015 （after the second intervention） and Jan.-Mar. 2016 （after the third intervention）. RESULTS： The reasonable rate of Ribonucleic acid Ⅱ for injection was 77.34％ before intervention， and 83.25％， 83.64％， 95.12％ after the first， second and third intervention respectively； the difference was statistically significant compared to before intervention （P＜0.05）. The irrational types included inappropriate indications， unsuitable treatment course， inappropriate usage and dosage， and unsuitable drug combination， etc. The percentage of these irrational types decreased from 2.96％， 4.93％， 13.79％ and 0.99％ before intervention to 1.63％， 0， 3.25％ and 0 after the third intervention， respectively. The utilization rate of Ribonucleic acid Ⅱ for injection was reduced from 8.81％ before intervention to 3.93％ after the third intervention， the differences were statically significant （P＜0.05）. CONCLUSIONS： The comprehensive intervention model combined with multiple intervention methods can promote the rational use of Ribonucleic acid Ⅱ for injection. It is suggested to further study and evaluate the intervention effect of this model on other adjuvant drugs for cancer therapy.